UK NSC blood spot task group (BSTG)

The blood spot task group (BSTG) identifies practical and innovative approaches to help researchers and others develop evidence that can help the UK National Screening Committee (UK NSC) make good recommendations.

Membership

Chair

David Elliman, Clinical lead for Newborn Blood Spot Screening Programme, Clinical Advisor to UK NSC, Consultant Great Ormond Street Hospital

Members

  • Amy Jayne McKnight, Northern Ireland Rare Disease and Congenital Anomaly Registry (NIRADCAR)

  • Anneke Lucassen, Professor of Genomic Medicine and consultant in clinical genetics at the University of Oxford and바카라 사이트¯UK NSC바카라 사이트¯member 

  • Anupam Chakrapani, Consultant in Metabolic Medicine, Great Ormond Street Hospital, and Chair of Inherited Metabolic Disorders Newborn Screening Advisory Board 

  • Catherine Joynson, Head of Engagement at UK Biobank 

  • Christine Cavanagh, midwife and former national manager of NHS Newborn Blood Spot Screening Programme 

  • Ellen Thomas, Chief Medical Officer, Genomics England 

  • Felicity Boardman, Professor of Social Science in Medicine, University of Warwick and member of바카라 사이트¯UK NSC Fetal, Maternal and Child Health (FMCH)바카라 사이트¯expert group 

  • Gail Walshe, former Director of Participation and Regional Development, Contact 

  • Gina Brondel, National Congenital and Rare Diseases Registration Service (NCARDRS), England 

  • Graham Shortland, consultant paediatrician and vice-chair of바카라 사이트¯ the UK NSC 

  • Heather Payne, Consultant Paediatrician, Senior Medical Officer for Maternal and Child Health, Welsh 바카라 사이트 

  • Helen Lewis-Parmar, Consultant in Public Health, and Senior Clinical Lead for Antenatal and Newborn Screening, Vaccination and Screening Directorate, NHS England 

  • Jane Fisher, Director, Antenatal Results and Choices (ARC), patient and public voice (PPV) member of바카라 사이트¯FMCH바카라 사이트¯expert group 

  • Jim Bonham, Laboratory Advisor to the바카라 사이트¯NHS Newborn Blood Spot바카라 사이트¯Screening Programme 

  • Liz Robinson, Newborn Pathway Senior Development Manager,바카라 사이트¯NHSE 

  • Llion Davies,바카라 사이트¯Congenital Anomaly Register and Information Service (CARIS), Public Health Wales NHS Trust 

  • Mariska Leeflang, Full Professor, Epidemiology and Data Science, University of Amsterdam 

  • Nick Meade, Director of Policy, Genetic Alliance UK 

  • Oliver Rivero-Arias, Associate Professor and Senior Health Economist, University of Oxford, and member of바카라 사이트¯FMCH바카라 사이트¯expert group 

  • Rachael Wood, Congenital Conditions and Rare Diseases Registration and Information Service for Scotland (CARDRISS) 

  • Rachel Knowles, Chair of the Antenatal and Newborn (ANNB) Research, Innovation and Development Advisory Committee (RIDAC), Principal Clinical Research Fellow at UCL and Clinical Advisor to the바카라 사이트¯NBS바카라 사이트¯screening programme at NHS England 

  • Robin Lachmann, Consultant in Inherited Metabolic Disease, National Hospital for Neurology and Neurosurgery, London, National Specialty Advisor for Metabolic Disorders, and member of바카라 사이트¯FMCH바카라 사이트¯expert group 

  • Sarah Stevens,바카라 사이트¯National Congenital Anomaly and Rare Disease Registration Service (NCARDRS),바카라 사이트¯NHSE 

  • Sharon Hillier, Director, Screening Division, Public Health Wales,바카라 사이트¯UK NSC바카라 사이트¯member and chair of the바카라 사이트¯FMCH바카라 사이트¯expert group 

  • Sian Taylor-Phillips, Professor of Population Health, Warwick Medical School, University of Warwick,바카라 사이트¯UK NSC바카라 사이트¯member and chair of바카라 사이트¯UK NSC바카라 사이트¯research and methodology group (RMG) 

  • Stuart Moat, Consultant Clinical Biochemist, Director of the Wales Newborn Screening Laboratory and Clinical Lead for the Metabolic Biochemistry Laboratory, University Hospital of Wales 

  • Susan Spillane, Deputy Director, Health Technology Assessment, Health Information and Quality Authority Ireland 

Participant observers 

  • Amanda Hogan, Newborn and SCT pathway implementation lead, Vaccinations and Screening Directorate, ANNB Screening Programmes 

  • Carol Beattie, Northern Ireland Senior Medical Officer 

  • David Tucker, CARIS, Public Health Wales NHS Trust 

  • Ellen Crushell, Consultant Paediatrician, Republic of Ireland  

  • Helen Tutt, Policy Lead for Screening, Welsh 바카라 사이트 

  • Lisa Douet, National Institute for Health and Care Research (NIHR) 

  • Ray Smith, Head of National Screening Policy, DHSC 

  • Tasmin Sommerfield, Consultant in Public Health Medicine for National Screening Programmes, National Clinical Advisor for Screening, NHS National Services Scotland

  • Tsitsi Muchayingeyi, Screening Policy Lead, DHSC

Terms of reference

BSTG terms of reference.

Meetings

The BSTG met for the first time on 29 April 2022.

BTSG discussions feed into policy development and are therefore confidential. 

However, the group publishes summary meeting notes so they may be shared for input and discussion by interested stakeholders.  

The BTSG provides updates on its work and outputs at the UK NSC Fetal, Maternal and Child Health (FMCH) group meetings 3 times a year.

Contact details

uknsc@dhsc.gov.uk